title: Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
abstract: OBJECTIVE
  We investigated whether KIF6 Trp719Arg genotypes affect cardiovascular outcomes and efficacy of statin therapy in patients with type 2 diabetes mellitus undergoing hemodialysis.
  
  
  RESULTS
  We conducted a post hoc analysis of the 4D-study, a randomized trial including 1255 patients. Patients were randomly assigned to double-blind treatment with either 20mg of atorvastatin (n = 619) or placebo (n = 636) once daily and followed for 4 years (median). DNA was available for 1232 patients and we assessed KIF6 Trp719Arg genotypes by PCR and subsequent restriction digest. Carriers of the Arg719 allele showed no increased prevalence of cardiovascular disease. The incidence of cardiac death, MI, and stroke did not differ across KIF6 genotypes, irrespective of whether the patients were treated with atorvastatin or not.
  
  
  CONCLUSIONS
  In patients with type 2 diabetes mellitus on hemodialysis, KIF6 Trp719Arg genotypes were not associated with adverse cardiovascular outcomes during follow-up or with the efficacy of atorvastatin therapy.
authors.affiliation: Department of Clinical Chemistry, University Medical Center, Hugstetter Straße 55, D-79106 Freiburg, Germany. michael.marcus.hoffmann@uniklinik-freiburg.de
authors.forename: Michael M
authors.initials: MM
authors.lastname: Hoffmann
authors.forename: Winfried
authors.initials: W
authors.lastname: März
authors.forename: Bernd
authors.initials: B
authors.lastname: Genser
authors.forename: Christiane
authors.initials: C
authors.lastname: Drechsler
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
mesh_terms: D000368:Aged; D000704:Analysis of Variance; D050197:Atherosclerosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000235:genetics / Q000401:mortality / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D003928:Diabetic Nephropathies / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D020022:Genetic Predisposition to Disease; D005858:Germany; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016547:Kinesins / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011758:Pyrroles / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects / Q000401:mortality; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin; C526774:KIF6 protein, human; D016547:Kinesins